Literature DB >> 25365987

MSCs isolated from patients with ischemic vascular disease have normal angiogenic potential.

Clara Sanz-Nogués1, Timothy O'Brien1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25365987      PMCID： PMC4429747          DOI： 10.1038/mt.2014.191

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  16 in total

1.  Combination stem cell therapy for the treatment of severe limb ischemia: safety and efficacy analysis.

Authors:  Gabriel P Lasala; Jose A Silva; Philip A Gardner; Jose J Minguell
Journal:  Angiology       Date:  2010-05-24       Impact factor: 3.619

2.  Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair.

Authors:  Xi-Ping Huang; Zhuo Sun; Yasuo Miyagi; Heather McDonald Kinkaid; Li Zhang; Richard D Weisel; Ren-Ke Li
Journal:  Circulation       Date:  2010-11-22       Impact factor: 29.690

Review 3.  Immunological aspects of allogeneic mesenchymal stem cell therapies.

Authors:  Matthew D Griffin; Thomas Ritter; Bernard P Mahon
Journal:  Hum Gene Ther       Date:  2010-12       Impact factor: 5.695

4.  Finding fluorescent needles in the cardiac haystack: tracking human mesenchymal stem cells labeled with quantum dots for quantitative in vivo three-dimensional fluorescence analysis.

Authors:  Amy B Rosen; Damon J Kelly; Adam J T Schuldt; Jia Lu; Irina A Potapova; Sergey V Doronin; Kyle J Robichaud; Richard B Robinson; Michael R Rosen; Peter R Brink; Glenn R Gaudette; Ira S Cohen
Journal:  Stem Cells       Date:  2007-05-10       Impact factor: 6.277

Review 5.  Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?

Authors:  Matthew D Griffin; Aideen E Ryan; Senthilkumar Alagesan; Paul Lohan; Oliver Treacy; Thomas Ritter
Journal:  Immunol Cell Biol       Date:  2012-12-04       Impact factor: 5.126

6.  Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies.

Authors:  A Stolzing; E Jones; D McGonagle; A Scutt
Journal:  Mech Ageing Dev       Date:  2007-12-17       Impact factor: 5.432

7.  Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease.

Authors:  Christopher Heeschen; Ralf Lehmann; Jörg Honold; Birgit Assmus; Alexandra Aicher; Dirk H Walter; Hans Martin; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Circulation       Date:  2004-03-22       Impact factor: 29.690

Review 8.  Why are MSCs therapeutic? New data: new insight.

Authors:  A I Caplan
Journal:  J Pathol       Date:  2009-01       Impact factor: 7.996

Review 9.  Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia.

Authors:  Aaron Liew; Timothy O'Brien
Journal:  Stem Cell Res Ther       Date:  2012-07-30       Impact factor: 6.832

10.  Bone marrow alterations and lower endothelial progenitor cell numbers in critical limb ischemia patients.

Authors:  Martin Teraa; Ralf W Sprengers; Peter E Westerweel; Hendrik Gremmels; Marie-José T H Goumans; Tom Teerlink; Frans L Moll; Marianne C Verhaar
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240
View more
  3 in total

1.  Donor variability among anti-inflammatory pre-activated mesenchymal stromal cells.

Authors:  Andrea Gray; Rene S Schloss; Martin Yarmush
Journal:  Technology (Singap World Sci)       Date:  2016-09

2.  Insights into Inflammatory Priming of Adipose-Derived Mesenchymal Stem Cells: Validation of Extracellular Vesicles-Embedded miRNA Reference Genes as A Crucial Step for Donor Selection.

Authors:  Enrico Ragni; Paola De Luca; Carlotta Perucca Orfei; Alessandra Colombini; Marco Viganò; Gaia Lugano; Valentina Bollati; Laura de Girolamo
Journal:  Cells       Date:  2019-04-23       Impact factor: 6.600

Review 3.  Secreted trophic factors of mesenchymal stem cells support neurovascular and musculoskeletal therapies.

Authors:  Heidi R Hofer; Rocky S Tuan
Journal:  Stem Cell Res Ther       Date:  2016-09-09       Impact factor: 6.832
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.